The main findings indicate that although recruitment to the trial was stopped early because of COVID-19, there was enough evidence to suggest that DIME is acceptable to people with T2D starting insulin and pre-COVID-19; it was feasible to deliver an intervention such as this. This evidence concerns the gene INS and type 2 diabetes mellitus.